KAT6A and ovarian carcinoma: Both KAT6A droplets and the interaction of KAT6A with PARP1 increased in response to olaparib + cisplatin treatment in PARPi‐resistant cancer cells but not in primary ovarian ones (Figure 6A,B), indicating that supplemental molecular mechanisms promote the formation of KAT6A LLPS and the interaction of KAT6A with PARP1 in PARPi‐resistant ovarian cancer cells.